Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
30
04
2020
accepted:
04
06
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.
Identifiants
pubmed: 32803133
doi: 10.1097/HS9.0000000000000433
pii: HemaSphere-2020-0130
pmc: PMC7410025
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e433Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
J Clin Rheumatol. 2019 Dec;25(8):329-334
pubmed: 31764493
Haematologica. 2017 Oct;102(10):e397-e399
pubmed: 28659336
Blood. 2013 Nov 7;122(19):3276-82
pubmed: 24004667
Clin Cancer Res. 2016 Apr 1;22(7):1572-82
pubmed: 26660519
Clin Infect Dis. 2020 Jul 28;71(15):740-747
pubmed: 32211844
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Haematologica. 2018 Jul;103(7):e307-e310
pubmed: 29472352
Br J Haematol. 2018 Sep;182(5):712-714
pubmed: 28737280
Mol Med. 2019 Jan 15;25(1):3
pubmed: 30646846
Am J Hematol. 2018 Aug;93(4):511-517
pubmed: 29280186
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
Clin Infect Dis. 2019 Jan 7;68(2):247-255
pubmed: 29800121
J Clin Oncol. 2009 Aug 10;27(23):3830-5
pubmed: 19506160
Blood. 2016 Sep 8;128(10):1321-8
pubmed: 27432877
Bone Marrow Transplant. 2020 Jun 8;:
pubmed: 32514158
Blood. 2014 Jul 24;124(4):503-10
pubmed: 24859363
Arthritis Rheumatol. 2019 Nov;71(11):1812-1823
pubmed: 31131994
Oncotarget. 2017 Jun 13;8(24):39218-39229
pubmed: 28424405
Br J Haematol. 2020 Apr;189(2):241-243
pubmed: 32173855